NeuroSense Therapeutics Ltd.
NRSN
$0.98
$0.011.03%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 75.64% | 44.94% | 216.77% | 13.70% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -12.93% | 11.40% | 433.86% | 10.09% | |
| Operating Income | 12.93% | -11.40% | -433.86% | -10.09% | |
| Income Before Tax | -1.35% | 68.03% | -36.48% | 41.22% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -1.35% | 68.03% | -36.48% | 41.22% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -1.35% | 68.03% | -36.48% | 41.22% | |
| EBIT | 12.93% | -11.40% | -433.86% | -10.09% | |
| EBITDA | 12.98% | -11.38% | -436.72% | -10.03% | |
| EPS Basic | 19.61% | 78.96% | 5.91% | 50.10% | |
| Normalized Basic EPS | 19.63% | 78.96% | 5.96% | -- | |
| EPS Diluted | 19.61% | 78.96% | 5.91% | 50.10% | |
| Normalized Diluted EPS | 19.63% | 78.96% | 5.96% | -- | |
| Average Basic Shares Outstanding | 26.12% | 51.78% | 45.05% | 17.79% | |
| Average Diluted Shares Outstanding | 26.12% | 51.78% | 45.05% | 17.79% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |